Samsung Electronics Hits Record High as AI Momentum Fuels Investor Optimism 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
U.S. Airline Flight Cancellations Surge After Venezuela Military Operation and FAA Airspace Closures 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Kia Targets 3.35 Million Global Vehicle Sales in 2026 Amid Steady Growth Outlook 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth 
KING OF PRUSSIA, Pa., March 14, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017 at 1:35 p.m. EDT in New York.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection). Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Sr. Director, Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
